Drug Trial Radar · NCT06446388
Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Jun 30, 2024
Primary completion
Jun 30, 2026
Study completion Dec 1, 2027
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of QLS31905 and/or QL1706 plus chemotherapy in patients with Claudin18.2-positive advanced solid tumors.
Conditions
- Advanced Solid Tumor
Interventions
QLS31905Drug
Administered as an intravenous infusion.
OxaliplatinDrug
130 mg/m2, intravenous infusion, D1, up to 8 cycles.
CapecitabineDrug
1000 mg/m2, oral, bid, D1-D14
GemcitabineDrug
1000 mg/m2 administered as IV infusion on D1/D8 of each cycle.
CisplatinDrug
25 mg/m2, intravenous infusion, D1/D8, up to 8 cycles.
QL1706Drug
5 mg/kg, intravenous infusion,D1
Chemotherapy drugDrug
Standard chemotherapy recommended by guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Approximately 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.